WallStreetZenWallStreetZen

NYSE: EHAB
Enhabit Inc Stock Forecast, Predictions & Price Target

Analyst price target for EHAB

Based on 3 analysts offering 12 month price targets for Enhabit Inc.
Min Forecast
$9.50-7.5%
Avg Forecast
$11.50+11.98%
Max Forecast
$14.00+36.32%

Should I buy or sell EHAB stock?

Based on 3 analysts offering ratings for Enhabit Inc.
Buy
Strong Buy
1 analysts 33.33%
Buy
0 analysts 0%
Hold
2 analysts 66.67%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their EHAB stock forecasts and price targets.

EHAB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-11
lockedlocked$00.00+00.00%2024-03-07
lockedlocked$00.00+00.00%2024-03-06

1 of 1

Forecast return on equity

Is EHAB forecast to generate an efficient return?

Forecast return on assets

Is EHAB forecast to generate an efficient return on assets?

EHAB revenue forecast

What is EHAB's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$1.1B+3.64%
Avg 2 year Forecast
$1.1B+8.56%
Avg 3 year Forecast
$1.2B+16.2%
EHAB's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

EHAB revenue growth forecast

How is EHAB forecast to perform vs Medical Care Facilities companies and vs the US market?
Company
4.94%
Industry
6.24%
Market
10.16%
EHAB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
EHAB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

EHAB vs Medical Care Facility Stocks

TickerPricePrice TargetUp/downsideConsensus
EHAB$10.27$11.50+11.98%Buy
CMPS$8.25$55.33+570.70%Strong Buy
INNV$4.00$6.50+62.50%Hold
AVAH$2.27$3.00+32.16%Strong Buy
SNDA$31.75N/AN/A

Enhabit Stock Forecast FAQ

Is Enhabit Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NYSE: EHAB) stock is to Buy EHAB stock.

Out of 3 analysts, 1 (33.33%) are recommending EHAB as a Strong Buy, 0 (0%) are recommending EHAB as a Buy, 2 (66.67%) are recommending EHAB as a Hold, 0 (0%) are recommending EHAB as a Sell, and 0 (0%) are recommending EHAB as a Strong Sell.

If you're new to stock investing, here's how to buy Enhabit stock.

What is EHAB's revenue growth forecast for 2024-2026?

(NYSE: EHAB) Enhabit's forecast annual revenue growth rate of 4.94% is not forecast to beat the US Medical Care Facilities industry's average forecast revenue growth rate of 6.24%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.16%.

Enhabit's revenue in 2024 is $1,046,300,000.On average, 3 Wall Street analysts forecast EHAB's revenue for 2024 to be $54,389,251,804, with the lowest EHAB revenue forecast at $54,022,962,974, and the highest EHAB revenue forecast at $54,629,849,848. On average, 3 Wall Street analysts forecast EHAB's revenue for 2025 to be $56,971,781,154, with the lowest EHAB revenue forecast at $55,874,218,719, and the highest EHAB revenue forecast at $58,311,295,844.

In 2026, EHAB is forecast to generate $60,979,591,852 in revenue, with the lowest revenue forecast at $59,163,946,824 and the highest revenue forecast at $62,795,236,880.

What is EHAB's forecast return on assets (ROA) for 2024-2027?

(NYSE: EHAB) forecast ROA is N/A, which is lower than the forecast US Medical Care Facilities industry average of N/A.

What is EHAB's Price Target?

According to 3 Wall Street analysts that have issued a 1 year EHAB price target, the average EHAB price target is $11.50, with the highest EHAB stock price forecast at $14.00 and the lowest EHAB stock price forecast at $9.50.

On average, Wall Street analysts predict that Enhabit's share price could reach $11.50 by Mar 11, 2025. The average Enhabit stock price prediction forecasts a potential upside of 11.98% from the current EHAB share price of $10.27.

What is EHAB's forecast return on equity (ROE) for 2024-2027?

(NYSE: EHAB) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.